Northern Trust’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-412,861
| Closed | -$19.8M | – | 4365 |
|
|
2020
Q1 | $19.8M | Sell |
412,861
-13,716
| -3% | -$638K | 0.01% | 1412 |
|
|
2019
Q4 | $20M | Sell |
426,577
-10,335
| -2% | -$457K | ﹤0.01% | 1717 |
|
|
2019
Q3 | $10.3M | Buy |
436,912
+169,890
| +64% | +$5.03M | ﹤0.01% | 2119 |
|
|
2019
Q2 | $8.03M | Buy |
267,022
+19,647
| +8% | +$450K | ﹤0.01% | 2287 |
|
|
2019
Q1 | $5.54M | Buy |
247,375
+76,362
| +45% | +$1.64M | ﹤0.01% | 2507 |
|
|
2018
Q4 | $3.11M | Buy |
171,013
+4,048
| +2% | +$63.5K | ﹤0.01% | 2793 |
|
|
2018
Q3 | $3.02M | Buy |
166,965
+15,145
| +10% | +$179K | ﹤0.01% | 2979 |
|
|
2018
Q2 | $1.51M | Sell |
151,820
-26,709
| -15% | -$184K | ﹤0.01% | 3337 |
|
|
2018
Q1 | $948K | Buy |
178,529
+40,814
| +30% | +$292K | ﹤0.01% | 3389 |
|
|
2017
Q4 | $1.17M | Buy |
137,715
+1,207
| +0.9% | +$14.8K | ﹤0.01% | 3359 |
|
|
2017
Q3 | $1.99M | Buy |
136,508
+6,382
| +5% | +$96.5K | ﹤0.01% | 3178 |
|
|
2017
Q2 | $2.44M | Buy |
130,126
+53,730
| +70% | +$1.21M | ﹤0.01% | 3058 |
|
|
2017
Q1 | $1.63M | Buy |
76,396
+2,208
| +3% | +$42.2K | ﹤0.01% | 3177 |
|
|
2016
Q4 | $1.13M | Buy |
+74,188
| New | +$1.01M | ﹤0.01% | 3314 |
|
Other funds holding RARX
Northern Trust's RARX Position: Q2 2020 in Review
Northern Trust sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 412,861 shares — an estimated $19.8M sold.
Northern Trust first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $20M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Northern Trust reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Northern Trust sold 412,861 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $19.8M.
- Northern Trust first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- Northern Trust's Ra Pharmaceuticals, Inc. Common Stock position peaked at $20M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Northern Trust's 13F filing for Q2 2020, filed 14 Aug 2020.